Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study (PAPA CABG)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2007 by McMaster University.
Recruitment status was:  Recruiting
Bristol-Myers Squibb
Information provided by:
McMaster University Identifier:
First received: May 26, 2006
Last updated: May 25, 2007
Last verified: May 2007

Main Research Question(s):

What is the effect of continuing aspirin until the time of coronary artery bypass graft surgery and of adding clopidogrel to aspirin after coronary artery bypass graft surgery for preventing blockage of coronary grafts, heart attack, stroke, and death? To reliably answer this question requires a large randomised trial. Before applying for a major grant from the Canadian Institute for Health Research to do the large study we would like to perform a small pilot study of 150 patients to demonstrate that it is feasible to recruit patients and to use a new test called “CT angiography” to determine whether the bypass grafts are still working or have become blocked.

(ii) Why is this research important? Coronary artery bypass surgery has made a very important contribution to improving the health and survival of patients with advanced coronary artery disease but still has many problems. One in 10 patients experiences a heart attack at the time of surgery, 1 in 20 experiences a heart attack, stroke, or death during hospitalization, and 1 in 4 patients has at least 1 blocked graft within 1 year of surgery. Antiplatelet drugs such as aspirin and clopidogrel are effective for preventing heart attacks, strokes and deaths but aspirin is usually stopped before coronary artery bypass graft surgery because of concerns about increasing the risk of bleeding. The effectiveness of the combination of clopidogrel and aspirin after surgery has not been evaluated. Our pilot study will provide key information about feasibility that will help us to design and perform a large definitive study in the future.

(iii) What is being studied? We will be looking at blood flow in bypass grafts as well as the occurrence of heart attack, stroke, and death. For safety we will be looking at bleeding, transfusion, and need for further surgery because of bleeding. We will also perform laboratory tests of platelet function to measure and compare the effect of the study treatments to prevent blood clots from forming.

Condition Intervention Phase
Coronary Artery Disease
Coronary Artery Bypass Grafting
Drug: Aspirin
Drug: Clopidogrel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery

Resource links provided by NLM:

Further study details as provided by McMaster University:

Primary Outcome Measures:
  • Graft patency, MI, Death, Stroke

Secondary Outcome Measures:
  • Bleeding, transfusion, re-exploration, Platelet function tests

Estimated Enrollment: 150
Study Start Date: July 2006
Detailed Description:

BACKGROUND: Platelets play a central role in the pathogenesis of ischemic complications (coronary artery bypass graft occlusion, myocardial infarction, stroke) following CABG surgery. Aspirin and clopidogrel used alone or in combination are effective for preventing ischemic complications in a broad range of high risk patients. However aspirin is usually discontinued before CABG surgery because of concerns about bleeding while the combination of aspirin and clopidogrel has not been evaluated for preventing ischemic complications after CABG surgery.

OBJECTIVES: The overall objectives of our research are to compare the effectiveness and safety of aspirin vs placebo before bypass surgery, and clopidogrel plus aspirin vs aspirin alone after surgery, on:

  1. blockage of coronary artery bypass grafts, MI, stroke, or death at 30 days
  2. bleeding and need for transfusion after surgery The specific objective of the present pilot study is to demonstrate the feasibility of recruiting patients undergoing CABG surgery into this study and of performing CT angiography at 30 days to determine graft patency. We will also measure the effect of different antiplatelet treatments on platelet function and blood markers of systemic inflammation during the first 48 hours after surgery.

DESIGN: This is a 2x2 factorial study of 150 elective CABG patients who will be randomized to receive low dose aspirin (81mg/d) or placebo for 5 days prior to surgery and aspirin 325mg loading dose followed by 81 mg/d plus clopidogrel 75 mg/d versus aspirin 81 mg/d and placebo post operatively.

OUTCOME: graft patency measured by CT angiography, MI, stroke, death, bleeding, transfusion requirement, need for re-exploration surgery, and laboratory measures of platelet function and aspirin resistance (including 11-dehydro thromboxane B2).

SAMPLE SIZE: This is a pilot study designed primarily to demonstrate feasibility. We propose to recruit a total of 150 patients over a 12 month period (2-4 per week).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients 18 years of age or older
  • Undergoing on-pump, elective coronary artery bypass grafting with at least 2 free grafts
  • Patient able to give informed consent

Exclusion Criteria:

  • planned date of surgery is <5 days from planned recruitment date
  • patient has clear indication for anticoagulation (eg. mechanical heart valve, atrial fibrillation) or ADP receptor antagonist (eg. drug-eluting stent)
  • allergy to or intolerance of aspirin or clopidogrel
  • history of bleeding diathesis, significant GI bleed, ICH, or liver failure
  • Patient has known renal failure or contraindication for Cardiac CT Angio
  • Patient has had previous cardiac surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00330772

Contact: Poonam Sharma, RN 905-521-2100 ext 44071
Contact: Jack CJ Sun, MD 905-537-3134

Canada, Ontario
Hamilton General Hospital Recruiting
Hamilton, Ontario, Canada, L8L 2X2
Contact: Poonam Sharma, RN    905-521-2100 ext 44071   
Contact: Jack CJ Sun, MD    905-537-3134   
Principal Investigator: Jack CJ Sun, MD         
Sub-Investigator: John W Eikelboom, MD,MSc         
Sub-Investigator: Tej Sheth, MD         
Sub-Investigator: Mary Lou Ellins, MD         
Sub-Investigator: Andre Lamy, MD         
Sub-Investigator: Kevin HT Teoh, MD         
Sub-Investigator: Sonia Anand, MD,MSc,PhD         
Sub-Investigator: Salim Yusuf, MD,DPhil         
Sponsors and Collaborators
Hamilton Health Sciences Corporation
Bristol-Myers Squibb
Principal Investigator: Jack CJ Sun, MD McMaster University
Study Director: John W Eikelboom, MD, MSc McMaster University
Study Chair: Kevin HT Teoh, MD McMaster University
Study Chair: Salim Yusuf, MD, DPhil McMaster University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00330772     History of Changes
Other Study ID Numbers: 06-091
Study First Received: May 26, 2006
Last Updated: May 25, 2007

Keywords provided by McMaster University:
Cardiac Surger
Coronary Artery Bypass Grafting
Graft patency

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Fibrinolytic Agents
Fibrin Modulating Agents
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents processed this record on April 27, 2017